Nektar Therapeutics (NKTR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$73.32-2.81%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — EPS loss narrows toward zero: EPS -2.3 vs target > -0.5.
Nektar is working to improve after recent losses. The company focuses on its REZOLVE-AA study and managing capital through stock offerings. Analysts expect smaller losses ahead, with EPS improving from -1.16 to -0.52 next quarter. Debt agreements provide financial flexibility.
Nektar faces ongoing losses and negative revenue growth of about -24%. Recent earnings missed expectations and clinical trial results have been negative. The company’s stock price is down over 25% from highs, reflecting weak momentum and elevated risk.
The market prices in about -24% revenue decline and a 28% discount to our fair value near $103. Our fair value is 26% below the Street median, reflecting cautious views on recovery. We see the price as justified given the losses and weak outlook.
Breaks if: No equity offerings or capital raises for 12 months
Nektar entered an underwriting agreement for a stock offering with several underwriters.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is in the biotechnology sector, focusing on advancing its drug candidates, but it faces volatility in management and financial performance.
The current valuation reflects a justified premium compared to peers, indicating that the market has low expectations for significant near-term improvements. There is a notable expectations gap, suggesting that the market is not fully pricing in potential positive outcomes from ongoing clinical trials.
Management is making progress in advancing its key drug into Phase 3 trials, which is a positive sign for long-term growth. However, recent financial performance has been weak, and the company remains loss-making, which adds to the uncertainty.
The long-term thesis hinges on the success of clinical trials, particularly for alopecia areata, and the overall performance of the healthcare sector. Additionally, the company's ability to maintain a strong financial position and manage risks associated with market conditions will be crucial.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on NKTR. However, concerns about maintaining a strong financial position due to capital raises present a challenge. Analyst Terry Chrisomalis maintained a 'Strong Buy' rating, citing the REZPEG catalyst as a positive factor.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: New negative clinical trial results reported
Nektar announced 52-week topline results from the REZOLVE-AA study of rezpegaldesleukin.
Breaks if: EPS loss worsens beyond -0.5 next quarter
Breaks if: revenue decline worsens beyond -10% YoY
Over the next 1 to 3 years, NKTR's outlook will depend on clinical advancements and sector dynamics. Not investment advice.